Paysign, Inc. (PAYS) is a Nevada-based provider of prepaid card programs, patient-affordability offerings, digital banking, and integrated payment processing, with particular exposure to pharmaceutical co-pay assistance. Four current, individually attributable analyst price targets were reviewed. Barrington Research (Gary Prestopino) maintained a $15 target, D.A. Davidson (Peter Heckmann) raised its target to $15 from $12 in late September 2026, and Lake Street Capital (Jacob Stephan) lifted its target to $15 from $13 in mid-September. Maxim Group (Michael Diana) holds a more conservative $12 target.
The resulting low-to-high range is $12 to $15, and the arithmetic mean of these four targets is $14.25, rounded to a $14 central target. The group skews firmly bullish — a "Strong Buy" or "Buy" consensus — but the reasoning differs by degree. The $15 targets emphasize the durability and upside of the patient-affordability growth story, while the $12 target reflects a more measured view of the same thesis. No single target should be read as more likely than another; the spread simply captures genuine disagreement about how far the momentum can extend.
At the November 9, 2026 close, PAYS traded near $12.50, meaning the $14 central target sits about 12% higher. That qualifies as a modest required move. Notably, the shares had climbed to 52-week highs during October and traded near the $14–$15 zone before a sharp single-session decline of roughly 15% on November 9, followed by a partial after-hours recovery. As a result, the $14 target largely represents a return toward levels the stock recently occupied rather than an entirely new high.
Fundamentally, the path toward $14 rests on continued execution. Paysign reported second-quarter revenue of $28.25 million and net profit of $6.76 million, a sharp improvement over the prior year's $19.08 million and $1.39 million. Management has guided full-year 2026 revenue to roughly $106.5 million–$110.5 million (30%–35% year-over-year growth), with net income of about $13 million–$16 million and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $30 million–$33 million.
The most important support is the patient-affordability segment, which grew revenue 81.9% year-over-year in the first quarter of 2026. As pharmaceutical companies expand programs that help patients cover co-pays and deductibles, Paysign's vertically integrated prepaid and processing model captures recurring revenue. The plasma business adds a second growth engine, with first-quarter plasma revenue up 24.9% year-over-year. A debt-free balance sheet with roughly $20.5 million in unrestricted cash provides flexibility, and analysts have repeatedly raised targets through 2026, signaling rising confidence in the earnings trajectory.
The principal risks are concentration and valuation. Patient-affordability demand is tied to pharmaceutical pricing and policy decisions, and any regulatory or pricing shift could dampen program growth. The stock's sharp November pullback demonstrates how quickly sentiment can reverse after a strong run, and multiple insider sales — including by the CFO and Chief Innovation Officer — have been reported, which can weigh on investor confidence. A re-rating to a lower multiple, weaker-than-expected net program additions, or a guidance shortfall would all make $14 harder to sustain.
The $15 level is a meaningful resistance zone, because it marks both the cluster of analyst targets and the area where the stock stalled before its November decline. Nearby support sits around $12, near Maxim Group's target and the recent pullback low. A durable move back through the mid-teens would require clearing the $15 zone, while a failure to hold near $12 could invite further consolidation.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary, and no explicit horizon was attached to every target reviewed here. Investors should watch quarterly patient-affordability program additions, plasma center counts, and full-year guidance, along with any analyst target revisions following results. Policy developments affecting pharmaceutical co-pay assistance and broader healthcare-sector sentiment are also relevant, as are insider transaction filings.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap name like PAYS, these signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Traders looking to complement fundamental research with systematic, data-driven timing may find the signals a useful addition to their process.
The $14 central target — the rounded mean of four current analyst targets spanning $12 to $15 — sits about 12% above the latest close, a modest hurdle that essentially marks a recovery toward levels PAYS recently traded near. The strongest supports are accelerating patient-affordability and plasma revenue, raised guidance, and a clean balance sheet; the chief obstacles are segment concentration, post-rally volatility, and insider selling. Analysts are broadly bullish but not unanimous, with the lone $12 target signaling that the runway is debatable. Whether PAYS reaches $14 will depend on sustained execution and sentiment, and no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PAYS has been loosely correlated with CLSK. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PAYS jumps, then CLSK could also see price increases.
| Ticker / NAME | Correlation To PAYS | 1D Price Change % | ||
|---|---|---|---|---|
| PAYS | 100% | -6.51% | ||
| CLSK - PAYS | 40% Loosely correlated | +5.18% | ||
| DAVE - PAYS | 39% Loosely correlated | +2.96% | ||
| PDFS - PAYS | 38% Loosely correlated | +6.72% | ||
| TOST - PAYS | 38% Loosely correlated | -1.22% | ||
| QTWO - PAYS | 38% Loosely correlated | -1.58% | ||
More | ||||
| Ticker / NAME | Correlation To PAYS | 1D Price Change % |
|---|---|---|
| PAYS | 100% | -6.51% |
| Computer Communications industry (167 stocks) | 5% Poorly correlated | -0.09% |